Trial Selection Rising

EGFR L858R

gastric cancer · Therapy Not Normalized

EGFR L858R is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.

Role evidence

Usage summary

Strongest role: Inclusion Required

Inclusion-required count: 5

Treatment-assignment count: 0

Stratification count: 0

Threshold snippets

Fragmentation view

Threshold count: 2

Common snippets: dMMR | BRAF V600E

Threshold label: Moderate

FDA CDx context

Mapping summary

CDx label: Fda Cdx Context Not Found

CDx maturity score: 1/5

Confidence: Medium

Patent-density signal

Diagnostic appendix

Signal count: 0

Recent signals: 0

Density label: Low

Source links

Evidence paths

https://clinicaltrials.gov/study/NCT04117958 | https://clinicaltrials.gov/study/NCT06075849 | https://clinicaltrials.gov/study/NCT05563766 | https://clinicaltrials.gov/study/NCT07333820 | https://clinicaltrials.gov/study/NCT05625737 | https://clinicaltrials.gov/study/NCT04260191 | https://clinicaltrials.gov/study/NCT05583201